UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE 13G

(Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 2)*

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

[  ] Rule 13d-1(b)

[  ] Rule 13d-1(c)

[X] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8 Pages

Item 1(a).                       Name of Issuer

The name of the issuer to which this filing on Schedule 13G/A relates is Intellia Therapeutics, Inc. (the “Company”).

Item 1(b).                      Address of Issuer’s Principal Executive Offices

The principal executive offices of the Company are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.

Item 2(a).                       Name of Person Filing

This Statement is being filed on behalf of Atlas Venture Fund IX, L.P. ("Atlas IX"), Atlas Venture Associates IX, L.P. ("AVA IX LP"), the sole general partner of Atlas IX, and Atlas Venture Associates IX, LLC ("AVA IX LLC"), the sole general partner of AVA IX LP.

Item 2(b).                      Address of Principal Business Office or, if none, Residence

The principal business address of each of Atlas IX, AVA IX LP, and AVA IX LLC is 46 Wareham Street, Boston MA, 02118.

Item 2(c).                       Citizenship

Each of Atlas IX, AVA IX LP and AVA IX LLC is organized under the laws of Delaware.

Item 2(d).                      Title of Class of Securities

The class of equity securities of the Company to which this filing on Schedule 13G/A relates is Common Stock, par value $0.0001 (“Common Stock”).

Item 2(e).                       CUSIP Number

The CUSIP number of the Company’s Common Stock is 45826J105.

Item 3.            If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:   Not applicable.

(a)                               [  ]  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)                              [  ]  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).

(c)                               [  ]  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)                             [  ]  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)                               [  ]  An investment adviser in accordance with §13d-1(b)(1)(ii)(E).

(f)                                [  ]  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

(g)                              [  ]  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

(h)                              [  ]  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

(i)                                  [  ]  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

(j)                                  [  ]  Group, in accordance with §240.13d-1(b)(1)(ii)(J).

[  ]  If this statement is filed pursuant to §240.13d-1(c), check this box.

Item 4.                                        Ownership

Item 4(a).  Amount beneficially owned

As of the close of business on December 31, 2018, Atlas IX is the record holder of 1,615,321 shares of Common Stock (the "Atlas Shares").  AVA IX LP is the sole general partner of Atlas IX.  AVA IX LLC is the sole general partner of AVA IX LP.  No person other than the respective owner referred to herein of the Atlas Shares is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of such Atlas Shares.  Each of Atlas IX, AVA IX LP, and AVA IX LLC disclaim beneficial ownership of the Atlas Shares except for such shares, if any, such person holds of record.

Item 4(b).  Percent of Class

As of the close of business on December 31, 2018, Atlas IX was the beneficial owner of 3.72% of the Common Stock, based on 43,419,303 shares outstanding as listed in the Company’s 10-Q filed on October 31, 2018.

Item 4(c).  Number of shares as to which the person has:

Item 5.                                        Ownership of Five Percent or Less of a Class

Each Filing Person has ceased to own beneficially more than 5% of the outstanding Common Stock of the Company.

Item 6.                                        Ownership of More than Five Percent on Behalf of Another Person

Not Applicable.

Item 7.           Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

Not Applicable.

Item 8.                                        Identification and Classification of Members of the Group

Not Applicable.  The Filing Persons expressly disclaim membership in a "group" as used in Rule 13d-5(b)(1).

Item 9.                                        Notice of Dissolution of Group

Not Applicable.

Item 10.                                Certification

Not Applicable.  This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b) or 13(d)-1(c).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  February 8, 2018

Exhibit A

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.